Drug Resistance 1: Antibodies and ADCs

• 2955 · PDF Systematic mechanistic profiling of ADC-resistant cancer cell lines Tingting Yuan, Yanqiu Bai, Lehua Cheng, Yanan Xu, Wenzhang Chen, Yan Gao, Zhuo Wen, Qiangqiang Fan, Zhengang Peng
• 2956 · PDF Determinants of sacituzumab govitecan therapeutic response in breast cancer models Carson J. Walker, Nina Dashti-Gibson, Julia E. Altman, Rachel K. Myrick, Emily K. Zboril, Oniya M. Smith, David C. Boyd, Bin Hu, Mikhail G. Dozmorov, Joshua C. Harrell
• 2957 · PDF Retinoic acid pathway regulates NECTIN4 expression and enhances NECTIN4-directed chimeric antigen receptor (CAR) T and antibody-drug conjugate therapies in bladder cancer Tamilla Nechiporuk, Sha Zhu, Yuxin Yang, Shivani Saxena, Jun Zhu, Rosalie Nolley, Imene Boukhalfa Ep Hanafi, Rhea Master, Elizabeth Yip, Kevin Chang, William Dougherty, Terence Friedlander, Vadim S. Koshkin, David Quigley, Jonathan Chou, Carissa E. Chu
• 2958 · PDF P-glycoprotein (ABCB1) overexpression confers resistance to the antibody-drug conjugate Enfortumab vedotin in EV-resistant organoid and PDX models Emilie Decaup, Claire Béraud, Isabelle Bernard-Pierrot, Guerric Gilbert, Clémentine Krucker, Xavier Gamé, Philippe Lluel, Nadège Bidan
• 2959 · PDF Improving the efficacy of B7-H3 targeting antibody-drug conjugates in TP53-deficient prostate cancer Javier Leo, Di Zhao
• 2960 · PDF Overcoming acquired and intrinsic resistance with an integrated ADC platform Jie Wen, Hao Cheng, Cheng Zhang, Bingrui Han
• 2961 · PDF Developing ADC-resistant tumor models for efficacy evaluation of next-generation anticancer therapies Jian Feng, Fuyin Zhao, Xinlong Dong, Aaron Li Hua, Chenpan Nie, Dorrith Verstegen, Caitlyn Hulsebosch, Wubin Qian, Sheng Guo, Jessie (Jingjing) Wang, Lenno Krenning, Marrit Putker, Ludovic Bourre, Peng Wang, Jun Zhou
• 2962 · PDF HER2 ADC resistance driven by IL-17 signaling and ROR1 upregulation: Overcoming DS-8201 resistance with BRY812 and BR111 Qianqian Tao, Qinqin Zhuang, Qizhe Wu, Lei Nie, Gang Chen, Haibin Wang, Jingtao Lu
• 2963 · PDF Development and characterization of a novel in vivo JIMT-1 DS8201a resistant model and its efficacy evaluation Qikuan Chen, Longyun Zhang, Ya Xu, Jingjing Zhang, Li Li, Greg Liang, Mingqi Shao, Fan Feng, Yinfei Yin
• 2964 · PDF Identification of synergistic dual payload combinations for antibody-drug conjugates to overcome resistance through resistance modeling Lili Chai, Yue Zhai, Yan Zhang, Ying Bi, Xue Yang, Zhengtai Li, Tiejun Bing
• 2965 · PDF Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeutic targeting Masahiro Kashima, Hidenori Kitai, Yukiko Yoshida, Yuriko Ishida, Yuma Sato, Daisuke Morinaga, Kosuke Tsuji, Shotaro Ito, Kanako C. Hatanaka, Takuma Kobayashi, Yoshiki Shinomiya, Teppei Konishi, Yutaka Hatanaka, Jun Sakakibara-Konishi, Satoshi Konno
• 2966 · PDF Zongertinib-tolerant cells enhanced sensitivity to Topo1 inhibition in Her2-positive NCSLC Kohei Maruyama, Ryohei Katayama
• 2967 · PDF Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics Tejaswini Reddy, Lei Kang, Hung Le, Senthil Damodaran, Kanwal Pratap Singh Raghav, Scott Kopetz, Jordi Rodon Ahnert, Ecaterina Elena Dumbrava, Timothy A. Yap, Stephen Williams, Mark J. Routbort, Keyur P. Patel, Funda Meric-Bernstam
• 2968 · PDF EGFR S442 mutation confers cetuximab resistance that can be overcome by ERBB2 blockade by trastuzumab-deruxtecan Neeraj Joshi, Sarah J. Harmych, Hidenori Tanaka, Galina Bogatcheva, Marisol A. Ramirez, Ramona Graves-Deal, Claiborne W. Tydings, Claudia C. Wahoski, Chelsie K. Sievers, Maria Johnson Irudayam, James N. Higginbotham, Frank L. Revetta, Zhiguo Zhao, Jeffrey L. Franklin, Binyam Yilma, Tina M. O'Grady, Stamatina Fragkogianni, Metamia Ciampricotti, M Kay Washington, Xingyi Guo, Allison S. Walker, Jens Meiler, Qi Liu, Robert J. Coffey, Eben L. Rosenthal, Bhuminder Singh
• 2969 · PDF B836: A novel bispecific antibody-drug conjugate (ADC) as a clinical candidate to overcome trastuzumab deruxtecan resistance Yi Zhao, Huahua Hao, Xin Yang, Weiwei Pan, XinxinLiang, Quanai Zhang, Xiaoxia Liu, Jingting Cui, Elizabeth Wu, Zhican Qu
• 2970 · PDF Limited efficacy of HER3-DXd in colorectal cancer PDX models reveals molecular resistance mechanisms and informs rational combinatorial strategies Preeti Kanikarla, Alexey Sorokin, Alisha Bent, Kelly Gale, Fengqin Gao, Zhensheng Liu, Kanwal Pratap Singh Raghav, Scott Kopetz
• 2971 · PDF In-depth profiling of SCLC models of acquired chemoresistance reveals SLFN11-dependent antibody-drug conjugate payload sensitivity and ATR inhibitor synergy Buesra Ernhofer, Lisa Glatt, Benjamin Morris, Beata Szeitz, Zsolt Megyesfalvi, Abigail Deloria, Diana Piesel, Laura Schnell, Kristiina Boettiger, Amirali Karimi, Monique Nilsson, Melinda Rezeli, Simon Heeke, John Victor Heymach, Clemens Aigner, Balazs Dome, Karin Schelch
• 2972 · PDF TROP2 upregulation and interaction with HER2 mediate trastuzumab resistance Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen
• 2974 · PDF The anticancer effect of TROP2-targeted antibody-drug conjugates (ADC) is potentially attenuated by dysregulated cholesterol metabolism in cancer cells Kimio Yonesaka, Yusuke Kawanaka, Takashi Kurosaki, Satomi Watanabe, Junko Tanizaki, Kazuko Sakai, Takeshi Teramura, Kazuto Nishio, Hidetoshi Hayashi
• 2975 · PDF Q702 enhances trastuzumab efficacy for HER2 + gastric cancer cells Mi Young Kim, Yoonji Lee, Kiyean Nam, Jin-Soo Kim

在会议检索中浏览本分会场